Connection

Stephen Tomlinson to Complement Inactivating Agents

Back to Details
This is a "connection" page, showing publications Stephen Tomlinson has written about Complement Inactivating Agents.
Stephen Tomlinson
Connection Strength
6.739
Complement Inactivating Agents
  1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
    View in: PubMed
    Score: 0.743
  2. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
    View in: PubMed
    Score: 0.724
  3. Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.
    View in: PubMed
    Score: 0.587
  4. Acute Complement Inhibition Potentiates Neurorehabilitation and Enhances tPA-Mediated Neuroprotection. J Neurosci. 2018 07 18; 38(29):6527-6545.
    View in: PubMed
    Score: 0.585
  5. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.538
  6. Injury site-specific targeting of complement inhibitors for treating stroke. Immunol Rev. 2016 11; 274(1):270-280.
    View in: PubMed
    Score: 0.523
  7. Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis. Clin Exp Immunol. 2015 Mar; 179(3):500-8.
    View in: PubMed
    Score: 0.465
  8. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54.
    View in: PubMed
    Score: 0.401
  9. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
    View in: PubMed
    Score: 0.380
  10. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011 Apr; 63(4):1076-85.
    View in: PubMed
    Score: 0.355
  11. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.181
  12. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.
    View in: PubMed
    Score: 0.181
  13. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
    View in: PubMed
    Score: 0.178
  14. Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System. Front Immunol. 2020; 11:566892.
    View in: PubMed
    Score: 0.171
  15. New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement. J Ocul Pharmacol Ther. 2017 06; 33(5):400-411.
    View in: PubMed
    Score: 0.134
  16. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.127
  17. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep. 2014 Aug 07; 8(3):818-30.
    View in: PubMed
    Score: 0.112
  18. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis. 2014 May; 234(1):237-43.
    View in: PubMed
    Score: 0.109
  19. Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett. 2012 Nov 30; 531(1):35-9.
    View in: PubMed
    Score: 0.099
  20. A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol. 2010; 703:137-49.
    View in: PubMed
    Score: 0.081
  21. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
    View in: PubMed
    Score: 0.044
  22. Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock. 2011 Feb; 35(2):134-40.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.